Exelixis | EXEL - Equity Capital And Reserves


Exelixis reported $1.94B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bayer EUR 28.85B 2.9B Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Eisai JPY 906.56B 7.57B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Exelixis USD 1.94B 225.57M Mar/2026
Genmab DKK 5.85B 96M Dec/2025
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 6.76B 647M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sanofi EUR 73.14B 1.43B Mar/2026
Takeda JPY 7.56T 215.7B Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026